Sinomab Bio B
Sinomab Bio B, also known as Sinomab Bioscience, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, the company has rapidly established itself in the biotechnology sector, focusing on the development of innovative therapies for autoimmune diseases and cancer. With a strong operational presence in Asia and expanding into global markets, Sinomab Bio B is recognised for its unique monoclonal antibody products, which leverage advanced technologies to enhance efficacy and safety. The company has achieved significant milestones, including successful clinical trials that underscore its commitment to addressing unmet medical needs. Sinomab Bio B's strategic position in the biopharmaceutical landscape is marked by its dedication to research and development, making it a key player in the industry.
DitchCarbon Score
How does Sinomab Bio B's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinomab Bio B's score of 35 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinomab Bio B's reported carbon emissions
In 2023, Sinomab Bio B reported total carbon emissions of approximately 2,723,220 kg CO2e. This figure includes Scope 1 emissions of about 31,960 kg CO2e, primarily from stationary combustion and fugitive emissions, and Scope 2 emissions of approximately 2,615,440 kg CO2e, mainly from purchased electricity and steam. Additionally, the company recorded Scope 3 emissions of around 75,820 kg CO2e, with significant contributions from business travel and waste generated in operations. Comparatively, in 2022, the total emissions were about 4,618,000 kg CO2e, with Scope 1 emissions at 58,000 kg CO2e and Scope 2 emissions at approximately 4,537,000 kg CO2e. The Scope 3 emissions for that year were significantly lower, at around 23,000 kg CO2e. Sinomab Bio B has not disclosed any specific reduction targets or initiatives as part of their climate commitments. However, the company is actively monitoring its emissions across all scopes, indicating a commitment to transparency in its environmental impact. The headquarters of Sinomab Bio B is located in Hong Kong (HK).
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 6,802.8 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 1,672,797.6 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sinomab Bio B is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
